OncLive SOSS

Updates in the Treatment of HR+ Breast Cancer - Episode 9

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

July 29, 2024

Kelly E. McCann, MD, PhD, Sara A. Hurvitz, MD, FACP , Virginia Kaklamani, MD, Mark D. Pegram, MD

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

EP. 2: Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

EP. 3: Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

EP. 4: Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

EP. 5: Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

EP. 6: Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

EP. 7: Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

EP. 8: Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

EP. 9: Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

EP. 10: ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

EP. 11: Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

EP. 12: Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

What are the other options for advanced HR+ disease(PI3K/AKT/mTOR inhibitors)?
- When and how are these being used? Are there any AEs of concern? How do you manage?
- ADCs

x